Germany’s pharma trade group, the VFA, has published a report on the opportunities presented by nanobiotechnology.
The report finds that Germany has a strong position in the field of nanotechnology, with 1,100 companies involved in the space, including in nanobiotechnology, the technology’s application in areas of medicine and life sciences.
"The still quite young field of research holds the potential to further improve diagnostic and therapeutic opportunities for diseases that were previously either incurable or insufficiently treatable"Current nanobiotechnological methods being used in the medical and pharmaceutical field include high-throughput screening to search for new target structures and substances, along with the use of nanoparticles in the releasee of drug substances at a local level.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze